Dicerna, an RNAi drug startup based in Boston (see related story, this issue), has appointed Roberto Guerciolini as senior vice president of pharmaceutical development.
Guerciolini, who is also a co-founder of Dicerna, was previously the senior vice president of development and chief medical officer of Sirna Therapeutics.
Before that, he served as senior director of clinical pharmacology and experimental medicine at Millennium Pharmaceuticals. He has also held various positions at Hoffman-La Roche and Schering-Plough.
He holds an MD in internal medicine from the University of Perugia Medical School and an MBA from the Hass School of Business at the University of California, Berkeley.